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BACKGROUND
Children who have been hospitalized with severe anemia in areas of Africa in which 
malaria is endemic have a high risk of readmission and death within 6 months 
after discharge. No prevention strategy specifically addresses this period.
METHODS
We conducted a multicenter, two-group, randomized, placebo-controlled trial in 
nine hospitals in Kenya and Uganda to determine whether 3 months of malaria 
chemoprevention could reduce morbidity and mortality after hospital discharge in 
children younger than 5 years of age who had been admitted with severe anemia. 
All children received standard in-hospital care for severe anemia and a 3-day 
course of artemether–lumefantrine at discharge. Two weeks after discharge, children 
were randomly assigned to receive dihydroartemisinin–piperaquine (chemopreven-
tion group) or placebo, administered as 3-day courses at 2, 6, and 10 weeks after 
discharge. Children were followed for 26 weeks after discharge. The primary out-
come was one or more hospital readmissions for any reason or death from the 
time of randomization to 6 months after discharge. Conditional risk-set modeling 
for recurrent events was used to calculate hazard ratios with the use of the Prentice–
Williams–Peterson total-time approach.
RESULTS
From May 2016 through May 2018, a total of 1049 children underwent randomiza-
tion; 524 were assigned to the chemoprevention group and 525 to the placebo 
group. From week 3 through week 26, a total of 184 events of readmission or death 
occurred in the chemoprevention group and 316 occurred in the placebo group 
(hazard ratio, 0.65; 95% confidence interval [CI], 0.54 to 0.78; P<0.001). The lower 
incidence of readmission or death in the chemoprevention group than in the pla-
cebo group was restricted to the intervention period (week 3 through week 14) 
(hazard ratio, 0.30; 95% CI, 0.22 to 0.42) and was not sustained after that time 
(week 15 through week 26) (hazard ratio, 1.13; 95% CI, 0.87 to 1.47). No serious 
adverse events were attributed to dihydroartemisinin–piperaquine.
CONCLUSIONS
In areas with intense malaria transmission, 3 months of postdischarge malaria 
chemoprevention with monthly dihydroartemisinin–piperaquine in children who had 
recently received treatment for severe anemia prevented more deaths or readmis-
sions for any reason after discharge than placebo. (Funded by the Research Coun-
cil of Norway and the Centers for Disease Control and Prevention; ClinicalTrials.gov 
number, NCT02671175.)
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Malaria Chemoprevention in Severe Anemia
Severe anemia contributes substan-tially to childhood mortality and is a leading cause of hospital admissions in 
areas of Africa in which malaria is endemic.1-5 
In the past few decades, most research on se-
vere anemia in Africa has focused on improv-
ing in-hospital care.4,6,7 However, in areas with 
intense malaria transmission, a substantial, 
potentially preventable component of the bur-
den occurs in the first few months after dis-
charge,8-12 with more deaths occurring during 
this time than during the in-hospital period.9,10 
Strategies that reduce the risk during this post-
discharge period may offer substantial public 
health gains.
A previous study from Malawi performed in 
areas in which malaria is endemic showed that 
children who were admitted with severe anemia 
did not have full hematologic recovery until at 
least 2 to 3 months after discharge.9 In areas 
with intense malaria transmission, a delay in 
hematologic recovery because of new or recur-
rent malaria infection is common and may con-
tribute to the high burden of adverse health 
outcomes after discharge.10,13 Currently, other 
than hematinic agents, no routine preventive 
strategies are provided after hospital discharge 
in areas in which malaria is endemic. We hypoth-
esized that administration of malaria prophy-
laxis during a limited period after transfusion 
would allow the bone marrow sufficient time to 
recover, resulting in a more sustained hemato-
logic recovery.14 Our previous trial in Malawi 
showed that 3 months of postdischarge ma-
laria chemoprevention with monthly treatment 
courses of artemether–lumefantrine prevented 
21% of deaths or readmissions within 6 months 
after discharge in children younger than 5 years 
of age who had been admitted with severe ma-
larial anemia and had been successfully treated 
with blood transfusion and parenteral antima-
larial drugs.11
In this trial, we aimed to confirm these 
promising findings. We assessed the efficacy of 
3 months of postdischarge malaria chemopre-
vention with monthly 3-day treatment courses of 
the long-acting antimalarial drug combination 
of dihydroartemisinin–piperaquine in prevent-
ing readmission or death after discharge in 




We conducted a parallel, two-group, individually 
randomized, double-blind, placebo-controlled, 
superiority trial in nine hospitals in Kenya and 
Uganda that were located in areas with moder-
ate-to-intense perennial malaria transmission.15 
The trial was approved by the ethics committees 
at the Kenya Medical Research Institute, Maker-
ere University School of Medicine, the Western 
Norway Regional Committee for Medical and 
Health Research Ethics, and the Liverpool School 
of Tropical Medicine. This article is published 
with the permission of the director of the Kenya 
Medical Research Institute. The Liverpool School 
of Tropical Medicine oversaw the trial, with sup-
port from its Global Health Trials Unit. The col-
laboration of the Centers for Disease Control 
and Prevention with the Center for Global Health 
Research, Kenya Medical Research Institute, in 
western Kenya provided infrastructural support 
for the trial in Kenya as well as centralized data 
management. The Makerere University School of 
Medicine provided oversight and technical and 
infrastructural support for the trial in Uganda. 
Written informed consent was obtained from 
the parents or guardians of the children. Dihydro-
artemisinin–piperaquine and placebo were sup-
plied free of charge by Alfasigma (Bologna, Italy), 
which had no role in the design, conduct, analy-
sis, or reporting of the trial. The funders had no 
role in the design or execution of the trial, the 
analysis or interpretation of the data, or the de-
cision to submit the manuscript for publication. 
The protocol,15 with the statistical analysis plan, 
is available with the full text of this article at 
NEJM.org. Three of the authors vouch for the 
accuracy and completeness of the data, and all 
the authors vouch for the fidelity of the trial to 
the protocol.
Randomization and Masking
Children younger than 5 years of age who had 
been admitted with severe anemia (at enroll-
ment, severe anemia was defined as a hemoglo-
bin level of <5 g per deciliter, a hematocrit of 
<15%, or clinical indication for blood transfu-
sion not caused by sickle cell disease, cancer, 
trauma, or elective surgery) and who fulfilled 
other eligibility criteria underwent randomiza-
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tion 2 weeks after discharge and were assigned 
in a 1:1 ratio to receive either postdischarge 
malaria chemoprevention (the chemoprevention 
group) or placebo. Full eligibility criteria are 
listed in the Supplementary Appendix, available 
at NEJM.org. Randomization was performed by 
means of a computer-generated randomization 
schedule prepared by an independent statistician 
with the use of permuted blocks of random size, 
stratified according to trial site and five body-
weight categories (additional details are provided 
in the Supplementary Appendix).
Sequentially numbered, sealed, opaque, identi-
cal envelopes were used to conceal trial-group 
assignments. The envelopes contained three other 
envelopes, each of which contained the trial drug 
or placebo for each course. Trial staff enrolled 
the children and performed the follow-up. The 
investigators, caregivers, and trial staff were 
unaware of the trial-group assignments.
Interventions
All children received standard in-hospital care 
for severe anemia and any other conditions; par-
enteral artesunate was administered if the child 
had severe malaria (on the basis of the treatment 
guidelines of the ministries of health of Kenya 
and Uganda). All children also received a 3-day 
course of artemether–lumefantrine at the time 
of discharge, regardless of their malaria status 
at admission, as soon as they were able to take 
oral medication. Two weeks after discharge, 
surviving children were randomly assigned to 
receive a standard 3-day treatment course of di-
hydroartemisinin–piperaquine or placebo at 2, 6, 
and 10 weeks after enrollment.15 Children re-
ceived iron supplementation (2 mg per kilogram 
of body weight per day) for 28 days after ran-
domization as monotherapy or combined with 
folic acid (130 to 520 μg per day). Caregivers 
were encouraged to ensure that children slept 
under an insecticide-treated bed net. The dihy-
droartemisinin–piperaquine and artemether–
lumefantrine doses were determined on the basis 
of guidelines of the World Health Organization 
(Tables S1 and S2 in the Supplementary Appendix).
Adherence to administration of dihydroarte-
misinin–piperaquine or placebo by the caregiver 
was assessed by trial staff who directly observed 
administration of the first dose of each course 
during home visits. Daily telephone contact with 
caregivers and random home visits were used to 
verify that the second and third doses of each 
course were administered. If children vomited 
within 30 minutes after taking a full dose of 
dihydroartemisinin–piperaquine or placebo, they 
received a second full dose. If the child vomited 
within 30 to 60 minutes after taking a full dose, 
an additional half dose was administered. If 
vomiting occurred after administration of any 
of the repeated doses, the child received arte-
mether–lumefantrine. If a child vomited after 
taking a dose at home, caregivers were instruct-
ed to inform the trial team on the same day to 
obtain a replacement dose.
Outcomes
All children were followed from the time of ran-
domization (day 14 after enrollment) through 
week 26 (Fig. S1). The primary outcome was one 
or more hospital readmissions for any reason or 
death from the time of randomization to 6 months 
after discharge. Key secondary outcomes included 
the individual components of the primary out-
come, hospital readmissions because of severe 
anemia or malaria, and outpatient clinic visits 
for any reason or for malaria-related reasons 
(see the Supplementary Appendix for additional 
outcomes). Safety outcomes included adverse 
events reported by trial clinicians, interruption 
of the trial regimen because of side effects, and 
prolongation of the corrected QT interval (QTc), 
measured by means of electrocardiography before 
the first dose of each course and at 4 to 6 hours 
after the third dose of each course.
Statistical Analysis
We calculated that a total of 1040 children (520 
per group) would be required to give the trial 
80% power to detect a 25% lower incidence of 
readmissions or deaths in the chemoprevention 
group than in the placebo group (1152 events vs. 
864 events per 1000 person-years), with a two-
sided P value of 0.05, assuming a 10% loss to 
follow-up.15
Analyses were performed with the use of 
Stata software, version 15.1 (StataCorp). The 
primary outcome was analyzed as recurrent 
time-to-event data with the use of the Prentice–
Williams–Peterson total-time approach,16 and re-
sults are reported as hazard ratios with 95% 
confidence intervals and P values. Data were 
censored at the date of the last contact (if chil-
dren were lost to follow-up) or at the end of the 
trial (at the end of week 26). Models included 
site and weight category as covariates to adjust 
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for stratification factors. The primary analysis 
was performed in the intention-to-treat popula-
tion and included new events occurring from the 
day of randomization (day 14 after enrollment) 
through week 26. We also prespecified the 
analysis to be stratified according to the period 
in the trial (intervention period [week 3 through 
week 14] or postintervention period [week 15 
through week 26]); the postintervention period 
would be the time when the direct pharmaco-
logic protective effect of dihydroartemisinin–
piperaquine would have waned.
Similar analyses were used for secondary 
time-to-event outcomes. Supportive analyses of 
the primary outcome with adjustment for covari-
ates and a per-protocol analysis were also per-
formed. Further sensitivity analyses to assess the 
robustness of the primary analysis were con-
ducted with the use of alternative time-to-event 
models and count models. All children contrib-
uted person-time to the primary analysis, and no 
imputation for missing outcome data was used. 
See the Supplementary Appendix for additional 
details regarding statistical methods and imputa-
tion methods used for missing covariable values.
R esult s
Trial Population
From May 2016 through May 2018, a total of 
1366 children were screened, and 1125 were as-
sessed for eligibility; 1049 children underwent 
randomization and were included in the intention-
to-treat population (524 in the chemoprevention 
group and 525 in the placebo group) (Fig. 1). The 
baseline characteristics were similar in the two 
groups (Table 1). Overall, 96.8% of children re-
ceived the prespecified number of courses (97.3% 
in the chemoprevention group and 96.3% in the 
placebo group), and 7.6% of children were with-
drawn or were lost to follow-up (8.4% in the 
chemoprevention group and 6.9% in the placebo 
group) (Table S3).
Primary Outcome
Overall, 500 events of readmission or death oc-
curred in 315 of 1049 children (30.0%): 184 events 
in the chemoprevention group and 316 events in 
the placebo group. Readmission or death occurred 
in 138 of 524 children (26.3%) in the chemopre-
vention group and in 177 of 525 (33.7%) in the 
placebo group. A total of 46 children (8.8%) in 
the chemoprevention group and 139 (26.5%) in 
the placebo group had multiple events (Table S4). 
At the end of week 26, the risk of readmission 
or death was 35% lower in the chemoprevention 
group than in the placebo group (hazard ratio, 
0.65; 95% confidence interval [CI], 0.54 to 0.78; 
P<0.001). During the intervention period (week 3 
through week 14 after randomization), the risk 
of death or readmission was 70% lower in the 
chemoprevention group than in the placebo 
group (hazard ratio, 0.30; 95% CI, 0.22 to 0.42; 
P<0.001); during the postintervention period 
(week 15 through week 26), the risk was 13% 
lower in the placebo group than in the chemo-
prevention group (hazard ratio, 1.13; 95% CI, 
0.87 to 1.47; P = 0.35) (Fig. 2). The difference in 
effect between the intervention and the post-
intervention periods was significant (Fig. S2). 
Similar results were seen in covariate-adjusted, 
subgroup, per-protocol, and sensitivity analyses 
(Figs. 2 and 3 and Figs. S3 through S5). The ef-
fect size of chemoprevention was larger in areas 
in which malaria transmission was higher (Fig. 
S6). The incidence of readmission or death was 
higher among children with severe malarial ane-
mia at the initial hospitalization than among 
children with nonmalarial anemia (41% vs. 9%), 
but this difference was not significant (Fig. 3). 
Children with nonmalarial anemia made up 15% 
of the population with severe anemia. Postdis-
charge malaria chemoprevention delayed the time 
to the first event of readmission or death (haz-
ard ratio, 0.58; 95% CI, 0.47 to 0.73); the 20th 
percentile of the time to the first event was 135 
days (95% CI, 123 to 149) in the chemopreven-
tion group and 55 days (95% CI, 43 to 66) in the 
placebo group.
Secondary Outcomes
Chemoprevention resulted in a 37% lower inci-
dence than placebo in the number of hospital 
readmissions for any reason at the end of week 
26 (hazard ratio, 0.63; 95% CI, 0.52 to 0.77). The 
hazard ratio was 0.31 (95% CI, 0.22 to 0.43) dur-
ing the intervention period and 1.09 (95% CI, 
0.83 to 1.42) during the postintervention period 
(Fig. 2). The incidences of hospital readmission 
because of severe malaria, severe anemia, severe 
malarial anemia, and other severe diseases were 
also significantly lower in the chemoprevention 
group than in the placebo group and were also 
lower during the intervention period than during 
the postintervention period. The hazard ratio for 
death from any cause was 0.74 at week 26 (95% 
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CI, 0.35 to 1.56), 0.08 during the intervention 
period (95% CI, 0.01 to 0.64), and 2.67 during the 
postintervention period (95% CI, 0.85 to 8.40).
In the analyses of the nonsevere outcomes, 
the hazard ratio for clinic visits for any illness 
was 0.88 (95% CI, 0.79 to 0.97), mainly reflect-
ing the treatment effect on uncomplicated ma-
laria (hazard ratio, 0.57; 95% CI, 0.48 to 0.69). 
The hazard ratio for clinic visits for illnesses 
unrelated to malaria was 1.09 (95% CI, 0.96 to 
1.24). At 26 weeks, there was no substantial ef-
fect on malaria infection (relative risk, 0.85; 95% 
CI, 0.69 to 1.05) and no substantial difference in 
mean hemoglobin levels (11.0 g per deciliter in 
Figure 1. Screening, Randomization, and Follow-up.
All 1049 children who underwent randomization were included in the intention-to-treat analysis. Among the children 
who had screening failure, 2 children were older than 59.5 months at the time of screening (i.e., about 2 weeks before 
randomization), 1 had a history of hypersensitivity to a trial drug, 6 had sickle cell disease, 14 were receiving a prohibit-
ed medication or were enrolled in another study that used a prohibited medication, 79 were unable to adhere to the 
follow-up schedule, 2 had a history of cardiac disorders, and blood transfusion had not yet been completed in 38.
1049 Underwent randomization
1125 Were assessed for eligibility
76 Were excluded
16 Did not meet inclusion criteria
35 Had participation declined
by caregiver
3 Died
22 Were lost to follow-up
1366 Children were screened for enrollment
241 Were excluded
142 Had screening failure
99 Had screening declined
by caregiver
524 Were assigned to and received post-
discharge malaria chemoprevention
525 Were assigned to and received placebo
25 Were excluded
1 Died
6 Had consent withdrawn
18 Were lost to follow-up
33 Were excluded
12 Died
7 Had consent withdrawn
14 Were lost to follow-up
499 Remained in trial until the end
of the intervention period
492 Remained in trial until the end
of the intervention period
19 Were excluded
4 Died
3 Had consent withdrawn
12 Were lost to follow-up
31 Were excluded
11 Died
5 Had consent withdrawn
15 Were lost to follow-up
468 Remained in trial until the end
of the postintervention period
473 Remained in trial until the end
of the postintervention period
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each group) (Table S5). The number of children 
who vomited at least once within 60 minutes 
after taking the trial medication or placebo was 
higher in the chemoprevention group (65 of 524 
[12.4%]) than in the placebo group (20 of 525 
[3.8%]) (Table S6).
Safety Outcomes
There were 284 serious adverse events in the 
chemoprevention group and 534 in the placebo 
group (P<0.001) (Table 2). In 12 children (2.3%) 
in the chemoprevention group and 30 (5.7%) in 
the placebo group, these events occurred within 
Table 1. Baseline Characteristics of the Children and Parents.*
Characteristic Chemoprevention (N = 524) Placebo (N = 525)
Children
Trial site — no. (%)
Uganda 347 (66.2) 345 (65.7)
Kenya 177 (33.8) 180 (34.3)
Male sex — no. (%) 280 (53.4) 265 (50.5)
Age — mo 26.8±15.5 26.3±14.8
Distance to clinic — km 27.5±22.6 29.1±14.8
Socioeconomic status level — no. (%)
Poor 173 (33.0) 177 (33.7)
Poorer 164 (31.3) 189 (36.0)
Poorest 187 (35.7) 159 (30.3)
Hemoglobin level before transfusion — g/dl 4.1±1.1 4.2±1.2
Hemoglobin level at randomization — g/dl 8.1±4.5 8.0±2.0
Body weight at randomization — kg 11.1±3.2 11.0±3.1
Severe malarial anemia — no. (%)† 436 (83.2) 454 (86.5)
Sleeps under a bed net — no./total no. (%) 317/380 (83.4) 318/385 (82.6)
Previous hospitalizations — no./total no. (%)
0 339/521 (65.1) 330/522 (63.2)
1  94/521 (18.0)  98/522 (18.8)
≥2  88/521 (16.9)  94/522 (18.0)
Readmitted after discharge, before randomization  
— no. (%)
14 (2.7) 18 (3.4)
Parents
Marital status of mother — no. (%)
Single 41 (7.8) 29 (5.5)
Married 425 (81.1) 435 (82.9)
Other  58 (11.1)  61 (11.6)
Father unemployed — no./total no. (%)  32/134 (23.9)  22/117 (18.8)
Education level of mother — no./total no. (%)
None  36/349 (10.3) 33/366 (9.0)
Primary 224/349 (64.2) 248/366 (67.8)
Secondary  84/349 (24.1)  72/366 (19.7)
Postsecondary or higher  5/349 (1.4) 13/366 (3.6)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding.
†  Severe malarial anemia was defined as severe anemia in the presence of any evidence of malaria infection detected by 
means of rapid diagnostic tests or microscopic examination or, if no diagnostic test result was available, any treatment 
with parenteral antimalarial drugs in the hospital.
n engl j med 383;23 nejm.org December 3, 20202248
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4 days after administration of dihydroartemis-
inin–piperaquine or placebo (P = 0.007) (Table 
S7). None of the events were judged by the site 
investigator to be related to the trial regimen. 
Data obtained with the use of the World Health 
Organization verbal autopsy questionnaire17,18 
and clinical notes suggested that of the 28 deaths, 
8 were due to severe malarial anemia, 9 to severe 
anemia, and 11 to other causes.
Electrocardiographic monitoring in 66 chil-
dren (33 in each group) showed that dihydroar-
temisinin–piperaquine was associated with an 
18.6 msec (95% CI, 15.6 to 21.8) increase in the 
QT interval corrected for heart rate according to 
Fridericia’s formula (QTcF) after the third dose 
of each course (all events of QTcF prolongation 
were asymptomatic), whereas placebo was not 
associated with an increase in the QTcF interval 
(change in QT interval, −1.8 msec; 95% CI, −5.3 
to 1.7). The mean QTcF prolongation was 8 msec 
less (95% CI, 1 to 15) after the third course than 
after the first course of dihydroartemisinin–
piperaquine. No QTcF values greater than 480 msec 
were observed (Table S8).
Discussion
A course of 3 months of postdischarge malaria 
chemoprevention with monthly dihydroartemis-
inin–piperaquine in children with severe anemia 
was highly effective and resulted in a 35% lower 
incidence of death or readmission for any reason 
than placebo. About one third of children in the 
placebo group died or were readmitted at least 
once during the 24 weeks after randomization, 
and many of the children were readmitted mul-
tiple times, findings that are consistent with the 
high postdischarge burden seen in previous 
studies in similar settings.9,10,19,20 The lower inci-
dence of readmission in the chemoprevention 
group than in the placebo group was mostly the 
result of the dihydroartemisinin–piperaquine 
treatment preventing events of severe malaria or 
severe malarial anemia, and the greatest reduc-
tions in the incidence of readmissions were ob-
served after a child had been hospitalized for 
severe malarial anemia and then discharged. 
Severe malarial anemia made up the majority 
(85%) of all initial admissions for severe anemia.
The beneficial effect of chemoprevention was 
restricted to the 12-week intervention period; 
during this time, the incidence of readmission 
or death in the chemoprevention group was 70% 
lower than that in the placebo group, the inci-
dence of readmission for severe malaria was 
87% lower, and the incidence of readmission for 
severe malarial anemia was 89% lower. The re-
sults observed in the extended follow-up period, 
starting 4 weeks after the third course, indicated 
that the beneficial effect was not sustained after 
about 14 weeks, when the protective piperaquine 
levels had waned. There was a nonsignificant 
increase in death from any cause (hazard ratio, 
2.67; 95% CI, 0.85 to 8.40) after 14 weeks — a 
result consistent with previous seasonal malaria 
chemoprevention studies in children.21,22 This 
could reflect a delay in the acquisition of protec-
tive immunity to malaria or a loss of protective 
immunity, but the result may also be artificial 
because of factors relating to frailty; in contrast 
to the placebo group, more of the vulnerable 
children in the chemoprevention group survived 
to contribute data to the postintervention period 
(e.g., of those who died during the postinterven-
tion period, 8 of 11 children in the chemopre-
vention group and 2 of 4 children in the placebo 
group had had a previous hospitalization before 
Figure 2 (facing page). Primary Outcome and Other 
 Efficacy Outcomes.
The primary outcome was one or more hospital readmis-
sions for any reason or death from the time of random-
ization to 6 months after discharge. The adjusted haz-
ard ratios were adjusted for site, body weight, number 
of previous hospital admissions, syndrome at the time 
of admission (severe malarial anemia or severe nonma-
larial anemia), age, hemoglobin level at randomization, 
distance to the hospital, and socioeconomic status. The 
widths of the confidence intervals have not been adjust-
ed for multiplicity, so the intervals should not be used 
to infer definitive treatment effects. The bars and the 
point estimates for the confidence intervals correspond 
to the crude hazard ratios. Severe anemia was defined 
as a hemoglobin level of less than 5 g per deciliter, a 
hematocrit of less than 15%, or a clinical indication for 
blood transfusion. Severe malarial anemia was defined 
as severe anemia in the presence of any evidence of 
malaria infection detected by means of rapid diagnostic 
tests or microscopic examination. Severe malaria-spe-
cific anemia was defined as severe anemia in the pres-
ence of malaria infection detected by means of micro-
scopic examination, with more than 5000 parasites per 
microliter. A secondary analysis of the primary outcome 
that excluded death or readmission due to trauma or 
cancer showed similar results because only one event 
in the chemoprevention group and no event in the pla-
cebo group was due to trauma or cancer.
n engl j med 383;23 nejm.org December 3, 20202250
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enrollment in the trial). Overall, however, the 
70% lower incidence of readmission or death in 
the chemoprevention group than in the placebo 
group during the intervention period outweighed 
the 13% higher risk in the chemoprevention group 
than in the placebo group during the extended 
follow-up period.
Although the incidence of readmission or 
death in the placebo group was highest in the 
first few months after discharge and declined 
gradually with longer follow-up, the incidence 
remained high in both groups during the 
3-month postintervention period, when about 
28% of the children died or were readmitted. It 
remains to be determined whether more sus-
tained reductions in readmission or death can 
be achieved by combining postdischarge ma-
laria chemoprevention with other malaria in-
terventions, such as a malaria vaccine and the 
provision of long-lasting insecticide-treated 
bed nets, or whether reductions can be achieved 
with longer periods of postdischarge malaria 
chemoprevention (e.g., up to 6 months) and iron 
supplementation, with or without folate. Other 
interventions, such as anthelmintics or those 
that address additional nutritional factors or re-
current bacterial infections, could also be con-
sidered, but the interventions may need to be 
tailored according to the prevalence of these local 
modifiable risk factors.
We chose dihydroartemisinin–piperaquine be-
cause the safety of this combination has been 
shown in children, and there is evidence for its 
effectiveness as seasonal malaria chemopreven-
tion or as monthly intermittent preventive therapy 
in children.23-26 Daily cotrimoxazole or monthly 
sulfadoxine–pyrimethamine, alone or combined 
with amodiaquine, was not considered because 
of high-grade resistance of the malaria parasite 
in southern Africa and East Africa.26,27 Dihydro-
artemisinin–piperaquine is known to provide at 
least 4 weeks of post-treatment prophylaxis,28 as 
compared with the 3 weeks of prophylaxis 
achieved with monthly artemether–lumefantrine 
in the previous postdischarge malaria chemo-
prevention trial.11 The initiation of dihydroarte-
misinin–piperaquine, rather than artemether–
lumefantrine, around the time of discharge could 
allow for pragmatic monthly administration 
starting 1 month after discharge. The longer 
duration of post-treatment prophylaxis achieved 
with dihydroartemisinin–piperaquine may explain 
the larger effect size during the 3-month inter-
vention period observed in the current trial (the 
risk of death or readmission was 70% lower in 
the chemoprevention group than in the placebo 
group) than in the previous trial, which used 
artemether–lumefantrine (41% lower risk in the 
chemoprevention group than in the placebo 
group).11 These results are also consistent with 
two other postdischarge intervention trials in-
volving Gambian children who had been hospi-
talized for severe anemia. These trials showed 
that near-complete chemoprevention of malaria 
after hospital discharge for the remainder of the 
malaria transmission season with either weekly 
prophylaxis with pyrimethamine–dapsone29 or 
monthly sulfadoxine–pyrimethamine30 also sig-
nificantly reduced the incidence of readmission 
for any reason30 or readmission for severe ane-
mia, both by 78%.29 These latter two studies 
were conducted before the widespread introduc-
tion of monthly seasonal malaria chemopreven-
tion in the Sahel region.31
These reductions in postdischarge events with 
the use of effective malaria chemoprevention are 
in contrast to the findings from a recent post-
discharge prevention trial involving severely ane-
mic children in similar settings in Uganda and 
Malawi in which malaria is endemic.12 Three 
months of daily cotrimoxazole did not improve 
6-month survival or reduce hospital readmis-
sions, possibly reflecting parasite resistance to 
antifolates in these regions,26,32 a low burden of 
nonmalarial febrile illness,12 or antimicrobial 
resistance.33
No serious adverse events attributable to 
dihydroartemisinin–piperaquine were observed. 
Asymptomatic QTc prolongation was, as expect-
ed, more common with dihydroartemisinin–
piperaquine than with placebo. However, no 
episode of QTc prolongation was associated with 
arrhythmias or clinical adverse events — a result 
consistent with other studies that used monthly 
dihydroartemisinin–piperaquine in pregnant 
women34 and in other groups.25 Only a few care-
givers withdrew their children from the trial 
because of perceived adverse events associated 
with the intervention, and these numbers were 
similar in the two trial groups.
Nevertheless, similar to seasonal malaria 
chemoprevention,21 when postdischarge malaria 
chemoprevention is implemented, clear health 
education for providers and the target popula-
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tion is required to achieve effective chemopre-
vention coverage under real-life conditions. Re-
cent health services research has shown that 
chemoprevention would most likely be accept-
able to caregivers and that a delivery system in 
which all three chemoprevention courses are 
given to the caregivers at the time of discharge 
for them to administer to their children would 
be likely to result in higher coverage than facili-
ty-based delivery that would require caregivers 
to return to the clinic.35,36 This method could be 
combined with text-message reminders sent to 
mobile telephones or with home visits by village 
health workers. Weekly prophylaxis with dihy-
droartemisinin–piperaquine after a loading dose, 
as compared with monthly dosing, could allow 
for more skipped doses without compromising 
effectiveness and should also be explored.37 
Modeling studies to determine the epidemio-
logic and geographical settings in which post-
discharge malaria chemoprevention would be a 
cost-effective intervention are merited.
The strengths of this trial include the high 
adherence to the chemoprevention regimen (98%) 
and the high percentage of children who re-
mained available for follow-up (>92%). Limita-
tions include the limited available diagnostic data 
for the nonmalaria causes of postdischarge re-
admissions or deaths. Furthermore, like previ-
ous postdischarge trials,11,12 the mortality in the 
placebo group was lower than expected, most 
likely reflecting enhanced access to standard 
care as the result of participation in a trial and 
the early diagnosis of events that would result in 
readmission.
In children living in areas with intense ma-
laria transmission who had undergone transfu-
sion and had been discharged from the hospital 
after treatment for severe anemia, 3 months of 
postdischarge malaria chemoprevention with 
dihydroartemisinin–piperaquine resulted in sub-
stantial benefits with respect to reducing the 
incidence of death or readmission for any reason 
after discharge.
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